# AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

> **NCT02151981** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 421 (actual)

## Conditions studied

- Anticancer Treatment

## Interventions

- **DRUG:** Chemotherapy
- **DRUG:** Cross-over to Osimertinib

## Key facts

- **NCT ID:** NCT02151981
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-04
- **Primary completion:** 2016-04-15
- **Final completion:** 2023-12-15
- **Target enrollment:** 421 (ACTUAL)
- **Last updated:** 2025-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02151981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02151981, "AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02151981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*